Business

Arcutis to Report Second Quarter Financial Results

WESTLAKE VILLAGE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company

articleArcutis Biotherapeutics, Inc.July 24, 20233/company/arcutis-biotherapeutics-inc/news/arcutis-to-report-second-quarter-financial-results-2023-07-24
Arcutis to Report Second Quarter Financial Results

About this update from Arcutis Biotherapeutics, Inc.

[{"type":"text","content":"WESTLAKE VILLAGE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 4:30 p.m. ET on Tuesday, August 8, 2023, to report its second quarter financial results. The schedule for the press release and conference call/webcast is as follows: Q2 2023 Press Release: Tuesday, August 8, 2023, after the close of the U.S. financial marketsQ2 2023 Earnings Call: Tuesday, August 8, 2023, at 4:30 p.m. ET A live webcast of the call and the presentation material will be available on the “Events” section of the Company’s investor website. An archived replay of the webcast will also be available on the Arcutis investor website following the call. About ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio that harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, seborrheic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, and Twitter. Forward-Looking StatementsThis press release contains “forward-looking” statements, including, among others, statements regarding its potential to address urgent needs and expectations with regard to the timing of data and regulatory events. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks a...

More updates from Arcutis Biotherapeutics, Inc.